- Home
- TMHC vs VKTX Comparison
TMHC vs VKTX Comparison
Compare TMHC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMHC
- VKTX
- Stock Information
- Founded
- TMHC 1936
- VKTX 2012
- Country
- TMHC United States
- VKTX United States
- Employees
- TMHC N/A
- VKTX N/A
- Industry
- TMHC Homebuilding
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TMHC Consumer Discretionary
- VKTX Health Care
- Exchange
- TMHC Nasdaq
- VKTX Nasdaq
- Market Cap
- TMHC 7.2B
- VKTX 7.2B
- IPO Year
- TMHC 2013
- VKTX 2015
- Fundamental
- Price
- TMHC $70.23
- VKTX $49.58
- Analyst Decision
- TMHC Buy
- VKTX Strong Buy
- Analyst Count
- TMHC 8
- VKTX 10
- Target Price
- TMHC $77.33
- VKTX $109.80
- AVG Volume (30 Days)
- TMHC 959.1K
- VKTX 6.8M
- Earning Date
- TMHC 10-23-2024
- VKTX 10-23-2024
- Dividend Yield
- TMHC N/A
- VKTX N/A
- EPS Growth
- TMHC N/A
- VKTX N/A
- EPS
- TMHC 7.54
- VKTX N/A
- Revenue
- TMHC $7,831,512,000.00
- VKTX N/A
- Revenue This Year
- TMHC $6.42
- VKTX N/A
- Revenue Next Year
- TMHC $7.33
- VKTX N/A
- P/E Ratio
- TMHC $9.28
- VKTX N/A
- Revenue Growth
- TMHC N/A
- VKTX N/A
- 52 Week Low
- TMHC $44.32
- VKTX $10.51
- 52 Week High
- TMHC $74.69
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- TMHC 51.11
- VKTX 31.07
- Support Level
- TMHC $69.47
- VKTX $62.50
- Resistance Level
- TMHC $74.69
- VKTX $70.41
- Average True Range (ATR)
- TMHC 2.26
- VKTX 5.16
- MACD
- TMHC -0.09
- VKTX -2.29
- Stochastic Oscillator
- TMHC 52.31
- VKTX 1.99
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West and Financial Services. The majority of the company's revenue is derived from its East Segment.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.